MECHANISTIC KIDNEY MODELS FOR CREATININE: RELEVANCE OF OCT2 TRANSPORT DRIVING FORCE TO PREDICTION OF CREATININE-DRUG INTERACTIONS

被引：0
|
作者：
Scotcher, Daniel [1 ]
Arya, Vikram [2 ]
Yang, Xinning [2 ]
Zhao, Ping [3 ]
Zhang, Lei K. [2 ]
Huang, Shiew-Mei [2 ]
Rostami-Hodjegan, Amin [1 ]
Galetin, Aleksandra [1 ]
机构：
[1] Univ Manchester, Manchester M13 9PL, Lancs, England
[2] US FDA, Rockville, MD 20857 USA
[3] Bill & Melinda Gates Fdn, Seattle, WA USA
来源：
DRUG METABOLISM AND PHARMACOKINETICS | 2020年 / 35卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
A12
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 11 条
  • [1] Mechanistic Models as Framework for Understanding Biomarker Disposition: Prediction of Creatinine-Drug Interactions
    Scotcher, Daniel
    Arya, Vikram
    Yang Xinning
    Zhao Ping
    Zhang Lei
    Huang Shiew-Mei
    Rostami-Hodjegan, Amin
    Galetin, Aleksandra
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (05): : 282 - 293
  • [2] MECHANISTIC PBPK MODELING OF CREATININE-DRUG INTERACTIONS IN CHRONIC KIDNEY DISEASE POPULATION.
    Takita, H.
    Scotcher, D.
    Chinnadurai, R.
    Kalra, P.
    Galetin, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S59 - S60
  • [3] MECHANISTIC PBPK MODELING OF CREATININE-DRUG INTERACTIONS IN CHRONIC KIDNEY DISEASE POPULATION.
    Takita, H.
    Scotcher, D.
    Chinnadurai, R.
    Kalra, P.
    Galetin, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S85 - S85
  • [4] Physiologically-Based Pharmacokinetic Modelling of Creatinine-Drug Interactions in the Chronic Kidney Disease Population
    Takita, Hiroyuki
    Scotcher, Daniel
    Chinnadurai, Rajkumar
    Kalra, Philip A.
    Galetin, Aleksandra
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (12): : 695 - 706
  • [5] Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2
    Tanihara, Yuko
    Masuda, Satohiro
    Inui, Ken-ichi
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 158
  • [6] MECHANISTIC MODELS FOR COPROPORPHYRIN I AND CREATININE AS ENDOGENOUS BIOMARKERS FOR TRANSPORTER DRUG-DRUG INTERACTIONS
    Galetin, Aleksandra
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S13 - S13
  • [7] A NOVEL OCT2/OCT3/MATE1 TRIPLE EXPRESSION MODEL FOR STUDYING ACTIVE CREATININE EXCRETION IN THE KIDNEY
    Huang, Yong
    Kosaka, Alan
    Huang, Jane
    Warren, Mark S.
    Zhang, John
    DRUG METABOLISM REVIEWS, 2012, 44 : 142 - 142
  • [8] Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium
    Dumitras, Swati
    Sechaud, Romain
    Drollmann, Anton
    Pal, Parasar
    Vaidyanathan, Sivakumar
    Camenisch, Gian
    Kaiser, Guenther
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (10) : 771 - 779
  • [9] IN VITRO-IN VIVO CORRELATION (IVIVC) OF DRUG INDUCED INHIBITION OF CREATININE TUBULAR SECRETION USING MDCK CELLS EXPRESSING OCT2/OAT2/OCT3/MATE1/MATE2K TRANSPORTERS.
    Zhang, X.
    Jiang, W.
    Li, C.
    Huang, J.
    Huang, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S60 - S60
  • [10] Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine
    Mueller, Fabian
    Koenig, Joerg
    Hoier, Eva
    Mandery, Kathrin
    Fromm, Martin F.
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (06) : 808 - 815
12